Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03819153




Registration number
NCT03819153
Ethics application status
Date submitted
18/01/2019
Date registered
28/01/2019
Date last updated
2/08/2024

Titles & IDs
Public title
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Scientific title
Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Secondary ID [1] 0 0
U1111-1217-6259
Secondary ID [2] 0 0
NN9535-4321
Universal Trial Number (UTN)
Trial acronym
FLOW
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Semaglutide
Treatment: Drugs - Placebo (semaglutide)

Experimental: Semaglutide - Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.

Placebo comparator: Placebo - Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.


Treatment: Drugs: Semaglutide
Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.

Treatment: Drugs: Placebo (semaglutide)
Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to first occurrence of a composite primary outcome event defined as persistent eGFR decline of greater than or equal to 50 percentage from trial start, reaching ESRD, death from kidney disease or death from cardiovascular disease
Timepoint [1] 0 0
Week 0 to month 61
Secondary outcome [1] 0 0
Annual rate of change in eGFR (chronic kidney disease - epidemiology collaboration (CKD-EPI)) (total eGFR slope)
Timepoint [1] 0 0
Week 0 to month 61
Secondary outcome [2] 0 0
Time to first occurrence of a composite cardiovascular major adverse cardiovascular event (MACE) endpoint consisting of: Non-fatal myocardial infarction, non-fatal stroke, and cardiovascular (CV) death
Timepoint [2] 0 0
Week 0 to month 61
Secondary outcome [3] 0 0
Time to occurrence of all-cause death
Timepoint [3] 0 0
Week 0 to month 61
Secondary outcome [4] 0 0
Time to occurrence of each of the individual components of the primary composite endpoint and of the confirmatory secondary MACE endpoint
Timepoint [4] 0 0
Week 0 to month 61
Secondary outcome [5] 0 0
Time to first occurrence of major adverse limb events (MALE), a composite endpoint consisting of: Acute limb ischemia hospitalisation and chronic limb ischemia hospitalisation
Timepoint [5] 0 0
Week 0 to month 61
Secondary outcome [6] 0 0
Annual rate of change in eGFR (CKD-EPI) (chronic eGFR slope)
Timepoint [6] 0 0
Week 12 to month 61
Secondary outcome [7] 0 0
Change in eGFR (CKD-EPI)
Timepoint [7] 0 0
Week 0, Week 12
Secondary outcome [8] 0 0
Change in eGFR (cystatin C CKD-EPI)
Timepoint [8] 0 0
Week 0, Year 3
Secondary outcome [9] 0 0
Relative change in urinary albumin-to-creatinine ratio (UACR)
Timepoint [9] 0 0
Week 0, Year 3
Secondary outcome [10] 0 0
Change in body weight
Timepoint [10] 0 0
Week 0, Year 3
Secondary outcome [11] 0 0
Change in glycosylated haemoglobin (HbA1c)
Timepoint [11] 0 0
Week 0, Year 3
Secondary outcome [12] 0 0
Change in systolic blood pressure
Timepoint [12] 0 0
Week 0, Year 3
Secondary outcome [13] 0 0
Change in diastolic blood pressure
Timepoint [13] 0 0
Week 0, Year 3
Secondary outcome [14] 0 0
Number of severe hypoglycaemic episodes
Timepoint [14] 0 0
Week 0 to month 61

Eligibility
Key inclusion criteria
* Male or female, age above or equal to 18 years at the time of signing informed consent. Japan: Male or female, age above or equal to 20 years at the time of signing informed consent
* Diagnosed with type 2 diabetes mellitus
* HbA1c less than or equal to 10% (less than or equal to 86 mmol/mol)
* Renal impairment defined either by:

1. serum creatinine-based eGFR greater than or equal to 50 and less than or equal to 75 mL/min/1.73 m^2 (CKD-EPI) and UACR greater than 300 and less than 5000 mg/g or
2. serum creatinine-based eGFR greater than or equal to 25 and less than 50 mL/min/1.73 m^2 (CKD-EPI) and UACR greater than 100 and less than 5000 mg/g
* Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated. Treatment dose must be stable for at least 4 weeks prior to the date of the laboratory assessments used for determination of the inclusion criteria for renal impairment and kept stable until screening
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations
* Use of any glucagon-like peptide-1 (GLP-1) receptor agonist within 30 days prior to screening
* Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 60 days prior to the day of screening
* Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
* Planned coronary, carotid or peripheral artery revascularisation
* Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/06/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/01/2024
Sample size
Target
Accrual to date
Final
3508
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Gosford Renal Research - Gosford
Recruitment hospital [2] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 0 0
Westmead Hospital_Northmead - Westmead
Recruitment hospital [4] 0 0
Core Research Centre - Milton
Recruitment hospital [5] 0 0
Monash Health Nephrology - Clayton
Recruitment hospital [6] 0 0
St Vincent's Hospital_Fitzroy_0 - Fitzroy
Recruitment hospital [7] 0 0
Monash University Clinical Trial Centre - Melbourne
Recruitment hospital [8] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4064 - Milton
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment postcode(s) [8] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Vermont
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Caba
Country [32] 0 0
Belgium
State/province [32] 0 0
Bonheiden
Country [33] 0 0
Belgium
State/province [33] 0 0
Brussel
Country [34] 0 0
Belgium
State/province [34] 0 0
Bruxelles
Country [35] 0 0
Belgium
State/province [35] 0 0
Edegem
Country [36] 0 0
Belgium
State/province [36] 0 0
Gent
Country [37] 0 0
Belgium
State/province [37] 0 0
Leuven
Country [38] 0 0
Belgium
State/province [38] 0 0
Liège
Country [39] 0 0
Belgium
State/province [39] 0 0
Roeselare
Country [40] 0 0
Brazil
State/province [40] 0 0
Ceara
Country [41] 0 0
Brazil
State/province [41] 0 0
Parana
Country [42] 0 0
Brazil
State/province [42] 0 0
Rio Grande Do Sul
Country [43] 0 0
Brazil
State/province [43] 0 0
Sao Paulo
Country [44] 0 0
Brazil
State/province [44] 0 0
Bahia
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Kozloduy
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Plovdiv
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Sliven
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Smolyan
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Sofia
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Stara Zagora
Country [51] 0 0
Canada
State/province [51] 0 0
Alberta
Country [52] 0 0
Canada
State/province [52] 0 0
British Columbia
Country [53] 0 0
Canada
State/province [53] 0 0
Newfoundland and Labrador
Country [54] 0 0
Canada
State/province [54] 0 0
Nova Scotia
Country [55] 0 0
Canada
State/province [55] 0 0
Ontario
Country [56] 0 0
Canada
State/province [56] 0 0
Quebec
Country [57] 0 0
China
State/province [57] 0 0
Beijing
Country [58] 0 0
China
State/province [58] 0 0
Jiangsu
Country [59] 0 0
China
State/province [59] 0 0
Shandong
Country [60] 0 0
France
State/province [60] 0 0
Annonay cedex
Country [61] 0 0
France
State/province [61] 0 0
BRON cedex
Country [62] 0 0
France
State/province [62] 0 0
Caen
Country [63] 0 0
France
State/province [63] 0 0
Grenoble - Cédex 09
Country [64] 0 0
France
State/province [64] 0 0
La Roche-sur-yon
Country [65] 0 0
France
State/province [65] 0 0
Le Coudray
Country [66] 0 0
France
State/province [66] 0 0
Le Creusot
Country [67] 0 0
France
State/province [67] 0 0
Paris
Country [68] 0 0
France
State/province [68] 0 0
Reims
Country [69] 0 0
France
State/province [69] 0 0
Saint Herblain
Country [70] 0 0
France
State/province [70] 0 0
Toulouse
Country [71] 0 0
France
State/province [71] 0 0
Venissieux
Country [72] 0 0
Germany
State/province [72] 0 0
Bad Mergentheim
Country [73] 0 0
Germany
State/province [73] 0 0
Bad Oeynhausen
Country [74] 0 0
Germany
State/province [74] 0 0
Düsseldorf
Country [75] 0 0
Germany
State/province [75] 0 0
Erlangen
Country [76] 0 0
Germany
State/province [76] 0 0
Essen
Country [77] 0 0
Germany
State/province [77] 0 0
Hamburg
Country [78] 0 0
Germany
State/province [78] 0 0
Münster
Country [79] 0 0
Germany
State/province [79] 0 0
Saint Ingbert-Oberwürzbach
Country [80] 0 0
Greece
State/province [80] 0 0
Attica
Country [81] 0 0
Greece
State/province [81] 0 0
Athens
Country [82] 0 0
Greece
State/province [82] 0 0
Lamia
Country [83] 0 0
Greece
State/province [83] 0 0
Rio, Patra
Country [84] 0 0
Greece
State/province [84] 0 0
Thessaloniki
Country [85] 0 0
Hungary
State/province [85] 0 0
Baranya Vármegye
Country [86] 0 0
Hungary
State/province [86] 0 0
Bács-Kiskun Vármegye
Country [87] 0 0
Hungary
State/province [87] 0 0
Hajdu-Bihar Varmegye
Country [88] 0 0
Hungary
State/province [88] 0 0
Somogy Vármegye
Country [89] 0 0
Hungary
State/province [89] 0 0
Szabolcs-Szatmar Varmegye
Country [90] 0 0
Hungary
State/province [90] 0 0
Budapest
Country [91] 0 0
Hungary
State/province [91] 0 0
Debrecen
Country [92] 0 0
Hungary
State/province [92] 0 0
Gyula
Country [93] 0 0
Hungary
State/province [93] 0 0
Siófok
Country [94] 0 0
Hungary
State/province [94] 0 0
Szombathely
Country [95] 0 0
India
State/province [95] 0 0
Andhra Pradesh
Country [96] 0 0
India
State/province [96] 0 0
Delhi
Country [97] 0 0
India
State/province [97] 0 0
Karnataka
Country [98] 0 0
India
State/province [98] 0 0
Kerala
Country [99] 0 0
India
State/province [99] 0 0
Maharashtra
Country [100] 0 0
India
State/province [100] 0 0
Tamil Nadu
Country [101] 0 0
India
State/province [101] 0 0
Telengana
Country [102] 0 0
India
State/province [102] 0 0
Uttar Pradesh
Country [103] 0 0
India
State/province [103] 0 0
West Bengal
Country [104] 0 0
India
State/province [104] 0 0
New Delhi
Country [105] 0 0
Israel
State/province [105] 0 0
Holon
Country [106] 0 0
Israel
State/province [106] 0 0
Jerusalem
Country [107] 0 0
Israel
State/province [107] 0 0
Kfar Saba
Country [108] 0 0
Israel
State/province [108] 0 0
Rehovot
Country [109] 0 0
Italy
State/province [109] 0 0
MI
Country [110] 0 0
Italy
State/province [110] 0 0
PA
Country [111] 0 0
Italy
State/province [111] 0 0
PI
Country [112] 0 0
Italy
State/province [112] 0 0
Bergamo
Country [113] 0 0
Italy
State/province [113] 0 0
Milano
Country [114] 0 0
Italy
State/province [114] 0 0
Roma
Country [115] 0 0
Japan
State/province [115] 0 0
Fukushima, Japan
Country [116] 0 0
Japan
State/province [116] 0 0
Hokkaido, Japan
Country [117] 0 0
Japan
State/province [117] 0 0
Kumamoto, Japan
Country [118] 0 0
Japan
State/province [118] 0 0
Miyazaki
Country [119] 0 0
Japan
State/province [119] 0 0
Chiba
Country [120] 0 0
Japan
State/province [120] 0 0
Fukui
Country [121] 0 0
Japan
State/province [121] 0 0
Fukuoka
Country [122] 0 0
Japan
State/province [122] 0 0
Gunma
Country [123] 0 0
Japan
State/province [123] 0 0
Hokkaido
Country [124] 0 0
Japan
State/province [124] 0 0
Ibaraki,
Country [125] 0 0
Japan
State/province [125] 0 0
Ibaraki
Country [126] 0 0
Japan
State/province [126] 0 0
Ishikawa
Country [127] 0 0
Japan
State/province [127] 0 0
Kanagawa
Country [128] 0 0
Japan
State/province [128] 0 0
Kyoto
Country [129] 0 0
Japan
State/province [129] 0 0
Okayama
Country [130] 0 0
Japan
State/province [130] 0 0
Osaka
Country [131] 0 0
Japan
State/province [131] 0 0
Saitama
Country [132] 0 0
Japan
State/province [132] 0 0
Tochigi
Country [133] 0 0
Japan
State/province [133] 0 0
Tokyo
Country [134] 0 0
Malaysia
State/province [134] 0 0
Wilayah Persekutuan Kuala Lumpur
Country [135] 0 0
Malaysia
State/province [135] 0 0
Alor Setar
Country [136] 0 0
Malaysia
State/province [136] 0 0
Ipoh, Perak
Country [137] 0 0
Malaysia
State/province [137] 0 0
Kuching
Country [138] 0 0
Malaysia
State/province [138] 0 0
Pulau Pinang
Country [139] 0 0
Malaysia
State/province [139] 0 0
Serdang
Country [140] 0 0
Mexico
State/province [140] 0 0
Hidalgo
Country [141] 0 0
Mexico
State/province [141] 0 0
Jalisco
Country [142] 0 0
Mexico
State/province [142] 0 0
México, D.F.
Country [143] 0 0
Mexico
State/province [143] 0 0
Sinaloa
Country [144] 0 0
Mexico
State/province [144] 0 0
Tamaulipas
Country [145] 0 0
Netherlands
State/province [145] 0 0
Alkmaar
Country [146] 0 0
Netherlands
State/province [146] 0 0
Almelo
Country [147] 0 0
Netherlands
State/province [147] 0 0
Almere
Country [148] 0 0
Netherlands
State/province [148] 0 0
Amersfoort
Country [149] 0 0
Netherlands
State/province [149] 0 0
Amsterdam
Country [150] 0 0
Netherlands
State/province [150] 0 0
Arnhem
Country [151] 0 0
Netherlands
State/province [151] 0 0
Hilversum
Country [152] 0 0
Netherlands
State/province [152] 0 0
Utrecht
Country [153] 0 0
Poland
State/province [153] 0 0
Bialystok
Country [154] 0 0
Poland
State/province [154] 0 0
Kielce
Country [155] 0 0
Poland
State/province [155] 0 0
Olsztyn
Country [156] 0 0
Poland
State/province [156] 0 0
Radom
Country [157] 0 0
Poland
State/province [157] 0 0
Szczecin
Country [158] 0 0
Poland
State/province [158] 0 0
Warszawa
Country [159] 0 0
Poland
State/province [159] 0 0
Zabrze
Country [160] 0 0
Russian Federation
State/province [160] 0 0
Barnaul
Country [161] 0 0
Russian Federation
State/province [161] 0 0
Chelyabinsk
Country [162] 0 0
Russian Federation
State/province [162] 0 0
Kazan
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Kemerovo
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Moscow
Country [165] 0 0
Russian Federation
State/province [165] 0 0
Novosibirsk
Country [166] 0 0
Russian Federation
State/province [166] 0 0
Penza
Country [167] 0 0
Russian Federation
State/province [167] 0 0
Saint Petersburg
Country [168] 0 0
Russian Federation
State/province [168] 0 0
Saint-Petersburg
Country [169] 0 0
Russian Federation
State/province [169] 0 0
Samara
Country [170] 0 0
Russian Federation
State/province [170] 0 0
Saratov
Country [171] 0 0
Russian Federation
State/province [171] 0 0
Stavropol
Country [172] 0 0
Russian Federation
State/province [172] 0 0
Ulianovsk
Country [173] 0 0
Russian Federation
State/province [173] 0 0
Voronezh
Country [174] 0 0
Russian Federation
State/province [174] 0 0
Yaroslavl
Country [175] 0 0
Russian Federation
State/province [175] 0 0
Yoshkar-Ola
Country [176] 0 0
Slovakia
State/province [176] 0 0
Bratislava
Country [177] 0 0
Slovakia
State/province [177] 0 0
Kosice
Country [178] 0 0
Slovakia
State/province [178] 0 0
Lubochna
Country [179] 0 0
Slovakia
State/province [179] 0 0
Lucenec
Country [180] 0 0
Slovakia
State/province [180] 0 0
Nitra
Country [181] 0 0
Slovakia
State/province [181] 0 0
Presov
Country [182] 0 0
Slovakia
State/province [182] 0 0
Trebisov
Country [183] 0 0
Slovakia
State/province [183] 0 0
Zilina
Country [184] 0 0
South Africa
State/province [184] 0 0
Gauteng
Country [185] 0 0
South Africa
State/province [185] 0 0
KwaZulu-Natal
Country [186] 0 0
South Africa
State/province [186] 0 0
Western Cape
Country [187] 0 0
Spain
State/province [187] 0 0
Barcelona
Country [188] 0 0
Spain
State/province [188] 0 0
Burela
Country [189] 0 0
Spain
State/province [189] 0 0
Getafe
Country [190] 0 0
Spain
State/province [190] 0 0
Lugo
Country [191] 0 0
Spain
State/province [191] 0 0
Valencia
Country [192] 0 0
Thailand
State/province [192] 0 0
Bangkok
Country [193] 0 0
Thailand
State/province [193] 0 0
Mueang Chiang Mai District
Country [194] 0 0
Turkey
State/province [194] 0 0
Ankara
Country [195] 0 0
Turkey
State/province [195] 0 0
Antalya
Country [196] 0 0
Turkey
State/province [196] 0 0
Aydin
Country [197] 0 0
Turkey
State/province [197] 0 0
Istanbul
Country [198] 0 0
Turkey
State/province [198] 0 0
Izmir
Country [199] 0 0
Turkey
State/province [199] 0 0
Kahramanmaras
Country [200] 0 0
Turkey
State/province [200] 0 0
Kocaeli
Country [201] 0 0
Ukraine
State/province [201] 0 0
Dnipro
Country [202] 0 0
Ukraine
State/province [202] 0 0
Ivano-Frankivsk
Country [203] 0 0
Ukraine
State/province [203] 0 0
Kharkiv
Country [204] 0 0
Ukraine
State/province [204] 0 0
Kyiv
Country [205] 0 0
Ukraine
State/province [205] 0 0
Poltava
Country [206] 0 0
Ukraine
State/province [206] 0 0
Zaporizhia
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Aberdeen
Country [208] 0 0
United Kingdom
State/province [208] 0 0
Birmingham
Country [209] 0 0
United Kingdom
State/province [209] 0 0
Cardiff
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Dundee
Country [211] 0 0
United Kingdom
State/province [211] 0 0
Edinburgh
Country [212] 0 0
United Kingdom
State/province [212] 0 0
Glasgow
Country [213] 0 0
United Kingdom
State/province [213] 0 0
Ipswich
Country [214] 0 0
United Kingdom
State/province [214] 0 0
London
Country [215] 0 0
United Kingdom
State/province [215] 0 0
Stevenage
Country [216] 0 0
United Kingdom
State/province [216] 0 0
Tooting

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novo Nordisk A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.
Trial website
https://clinicaltrials.gov/study/NCT03819153
Trial related presentations / publications
Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mahaffey KW, Mann JFE, Mersebach H, Perkovic V, Tuttle K, Pratley R. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009. Erratum In: Nephrol Dial Transplant. 2024 Mar 27;39(4):724. doi: 10.1093/ndt/gfad252.
Cohen S, Sternlicht H, Bakris GL. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 May;22(5):213-218. doi: 10.1007/s11892-022-01461-4. Epub 2022 Apr 20.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Transparency (dept. 1452)
Address 0 0
Novo Nordisk A/S
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03819153